- Report
- May 2026
- 177 Pages
Global
From €4035EUR$4,500USD£3,447GBP
- Report
- January 2026
- 186 Pages
Global
From €4035EUR$4,500USD£3,447GBP
- Report
- September 2025
- 185 Pages
Global
From €4035EUR$4,500USD£3,447GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- April 2026
- 30 Pages
Global
From €2466EUR$2,750USD£2,107GBP
- Report
- April 2026
- 30 Pages
Global
From €2466EUR$2,750USD£2,107GBP
- Report
- May 2026
- 100 Pages
Global
From €2420EUR$2,699USD£2,068GBP
- Report
- August 2026
- 566 Pages
Global
From €5245EUR$5,850USD£4,482GBP
- Report
- May 2026
- 30 Pages
Global
From €2466EUR$2,750USD£2,107GBP
- Report
- March 2026
- 150 Pages
Global
From €3362EUR$3,750USD£2,873GBP
- Report
- January 2026
- 450 Pages
Global
From €4483EUR$5,000USD£3,831GBP
- Report
- January 2026
- 180 Pages
Global
From €2690EUR$3,000USD£2,298GBP
- Report
- July 2026
- 130 Pages
Global
From €4259EUR$4,750USD£3,639GBP
- Report
- May 2026
- 120 Pages
Global
From €4259EUR$4,750USD£3,639GBP
- Report
- January 2026
- 120 Pages
Global
From €4259EUR$4,750USD£3,639GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2501EUR$2,789USD£2,137GBP
- Report
- May 2026
- 400 Pages
Global
From €4437EUR$4,949USD£3,791GBP
- Report
- May 2026
- 150 Pages
Global
From €2420EUR$2,699USD£2,068GBP
- Report
- April 2026
- 150 Pages
Global
From €2689EUR$2,999USD£2,298GBP
€3586EUR$3,999USD£3,064GBP
- Report
- July 2026
- 160 Pages
Global
From €3721EUR$4,150USD£3,179GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more